Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $93.6 million.

  • Rocket Pharmaceuticals' Cash from Investing Activities rose 1862.29% to $93.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.5 million, marking a year-over-year increase of 242.94%. This contributed to the annual value of $131.7 million for FY2024, which is 23430.34% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Cash from Investing Activities stood at $93.6 million, which was up 1862.29% from $31.8 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Investing Activities ranged from a high of $93.6 million in Q3 2025 and a low of -$140.8 million during Q4 2023
  • Over the past 5 years, Rocket Pharmaceuticals' median Cash from Investing Activities value was $23.5 million (recorded in 2022), while the average stood at $2.7 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 100804.05% in 2021, then tumbled by 74388.64% in 2022.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Cash from Investing Activities stood at $16.9 million in 2021, then crashed by 743.89% to -$108.6 million in 2022, then dropped by 29.67% to -$140.8 million in 2023, then soared by 73.1% to -$37.9 million in 2024, then surged by 347.2% to $93.6 million in 2025.
  • Its Cash from Investing Activities stands at $93.6 million for Q3 2025, versus $31.8 million for Q2 2025 and -$58.0 million for Q1 2025.